Journal of Bone and Mineral Metabolism

, Volume 33, Issue 1, pp 119–124 | Cite as

Prospective, mono-institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases

  • Annalisa Bramati
  • Serena Girelli
  • Gabriella Farina
  • Maria Chiara Dazzani
  • Valter Torri
  • Anna Moretti
  • Sheila Piva
  • Mariastella Dimaiuta
  • Nicla La Verde
Original Article

Abstract

The aim of our study was to investigate the occurrence of osteonecrosis of the jaw (ONJ) after implementation of dental preventive measures before starting bisphosphonates (BPs) therapy and during treatment. All consecutive patients with bone lesions eligible for BPs treatment were prospectively evaluated. Before starting BPs, each patient underwent a strict dental preventive program with a specialized odontoiatric team. The odontoiatric evaluation identified patients with oral pathologies or inadequate oral hygiene and provided a dental preventive treatment. From April 2007 to April 2012, 254 patients were enrolled. After excluding patients due to previous BPs treatment, 212 patients with a mean age of 74 years (range 37–95) were included. On average, patients received 9.7 treatment cycles (range 1–48). No ONJ was recorded (0.0 %; 95 % confidence interval [CI] 0.0–1.4). Comparing this risk with that observed in a previous cohort who did not receive dental prevention (16/186, 8.6 %; 95 % CI 4.2–15.3 %), we observed clear efficacy in preventing ONJ (relative risk reduction: 100 %, 95 % CI 86–100 %, P < 0.0001). We developed a strict three-step prevention program that is able to decrease ONJ incidence and the need for destructive surgery with permanent sequelae. We demonstrated that ONJ could be effectively prevented. We recommend a mandatory preventive program involving a multidisciplinary team for all patients starting BPs.

Keywords

Bisphosphonates Bone metastases Oral preventive program Osteonecrosis of the jaw (ONJ) 

Notes

Acknowledgments

This research was not funded by any sponsor.

Conflict of interest

All authors have no conflicts of interest.

References

  1. 1.
    Assael LA (2009) Oral bisphosphonates as a cause of bisphosphonate-related osteonecrosis of the jaws: clinical findings, assessment of risks, and preventive strategies. J Oral Maxillofac Surg 67:35–43PubMedCrossRefGoogle Scholar
  2. 2.
    Ruggiero SL, Dodson TB, Assael LA, Landesberg R, Marx RE, Mehrotra B (2009) American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws—2009 update. J Oral Maxillofac Surg 67:2–12PubMedCrossRefGoogle Scholar
  3. 3.
    Otto S, Schreyer C, Hafner S, Mast G, Ehrenfeld M, Stürzenbaum S, Pautke C (2012) Bisphosphonate-related osteonecrosis of the jaws—characteristics, risk factors, clinical features, localization and impact on oncological treatment. J Craniomaxillofac Surg 40:303–309PubMedCrossRefGoogle Scholar
  4. 4.
    Filleul O, Crompot E, Saussez S (2010) Bisphosphonate-induced osteonecrosis of the jaw: a review of 2,400 patient cases. J Cancer Res Clin Oncol 136:1117–1124PubMedCrossRefGoogle Scholar
  5. 5.
    Tarassoff P, Csermak K (2003) Avascular necrosis of the jaws: risk factors in metastatic cancer patients. J Oral Maxillofac Surg 61:1238–1239PubMedCrossRefGoogle Scholar
  6. 6.
    Troeltzsch M, Woodlock T, Kriegelstein S, Steiner T, Messlinger K, Troeltzsch M (2012) Physiology and pharmacology of nonbisphosphonate drugs implicated in osteonecrosis of the jaw. J Can Dent Assoc 78:c85PubMedGoogle Scholar
  7. 7.
    Flanagan AM, Chambers TJ (1991) Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone. Calcif Tissue Int 49:407–415PubMedCrossRefGoogle Scholar
  8. 8.
    Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep MM, Thesing CW, Bijvoet OL (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27–39PubMedGoogle Scholar
  9. 9.
    Löwik CW, van der Pluijm G, van der Wee-Pals LJ, van Treslong-De Groot HB, Bijvoet OL (1988) Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res 3:185–192PubMedCrossRefGoogle Scholar
  10. 10.
    Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA (1999) Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase. J Biol Chem 274:34967–34973PubMedCrossRefGoogle Scholar
  11. 11.
    Senaratne SG, Pirianov G, Mansi JL, Arnett TR, Colston KW (2000) Bisphosphonates induce apoptosis in human breast cancer cell lines. Br J Cancer 82:1459–1468PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Fournier P, Boissier S, Filleur S, Guglielmi J, Carbon F, Colombel M, Clezardin P (2002) Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res 62:6538–6544PubMedGoogle Scholar
  13. 13.
    Woo SB, Hellstein JW, Kalmar JR (2006) Systematic review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753–761PubMedCrossRefGoogle Scholar
  14. 14.
    Durie BG, Katz M, Crowley J (2005) Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99–102PubMedCrossRefGoogle Scholar
  15. 15.
    Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115–1117PubMedCrossRefGoogle Scholar
  16. 16.
    La Verde N, Bareggi C, Garassino M, Borgonovo K, Sburlati P, Pedretti D, Bianchi C, Perrone S, Mihali D, Cobelli S, Mantica C, Rizzo A, Farina G (2008) Osteonecrosis of the jaw (ONJ) in cancer patients treated with Bisphosphonates: how the knowledge of a phenomenon can change its evolution. Support Care Cancer 16:1311–1315PubMedCrossRefGoogle Scholar
  17. 17.
    Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukav V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA (2005) Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23:8580–8587PubMedCrossRefGoogle Scholar
  18. 18.
    Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M (2004) Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96:879–882PubMedCrossRefGoogle Scholar
  19. 19.
    Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, Pawlicki M, De Souza P, Zheng M, Urbanowitz G, Reitsma D, Seaman J (2004) Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo controlled trial. Cancer 100:2613–2621PubMedCrossRefGoogle Scholar
  20. 20.
    Lopez-Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez-Almazor ME (2012) Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta-analysis. Support Care Cancer 20:2985–2998PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Tunn UW, Stenzl A, Schultze-Seemann W, Strauss A, Kindler M, Miller K, Wirth MP, Zantl N, Schulze M, May C, Ruebel A, Birkholz K, Gruenwald V (2012) Positive effects of zoledronate on skeletal-related events in patients with renal cell cancer and bone metastases. Can J Urol 19:6261–6267PubMedGoogle Scholar
  22. 22.
    Van Poznak CH, Temin S, Yee GC, Janjan NA, Barlow WE, Biermann JS, Bosserman LD, Geoghegan C, Hillner BE, Theriault RL, Zuckerman DS, Von Roenn JH (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29:1221–1227PubMedCrossRefGoogle Scholar
  23. 23.
    Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137–145PubMedCrossRefGoogle Scholar
  24. 24.
    Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E, Bamias A (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117–120PubMedCrossRefGoogle Scholar
  25. 25.
    Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the jaw: a review of 282 patients. J Can Dent Assoc 77:b147PubMedGoogle Scholar
  26. 26.
    Yoneda T, Hagino H, Sugimoto T, Ohta H, Takahashi S, Soen S, Taguchi A, Toyosawa S, Nagata T, Urade M (2010) Bisphosphonate-related osteonecrosis of the jaw: position paper from the Allied Task Force Committee of Japanese Society for Bone and Mineral Research, Japan Osteoporosis Society, Japanese Society of Periodontology, Japanese Society for Oral and Maxillofacial Radiology, and Japanese Society of Oral and Maxillofacial Surgeons. J Bone Miner Metab 28:365–383PubMedCrossRefGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer Japan 2014

Authors and Affiliations

  • Annalisa Bramati
    • 1
  • Serena Girelli
    • 1
  • Gabriella Farina
    • 1
  • Maria Chiara Dazzani
    • 1
  • Valter Torri
    • 2
  • Anna Moretti
    • 1
  • Sheila Piva
    • 1
  • Mariastella Dimaiuta
    • 1
  • Nicla La Verde
    • 1
  1. 1.Department of OncologyA.O. Fatebenefratelli e OftalmicoMilanItaly
  2. 2.Laboratory of Methodology for Biomedical ResearchIRCCS-Istituto di Ricerche Farmacologiche “Mario Negri”MilanItaly

Personalised recommendations